Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Acquisition

3 Aug 2005 07:02

Marchpole Holdings PLC03 August 2005 FOR IMMEDIATE RELEASE 3 August 2005 Marchpole Holdings Plc ("Marchpole" or the "Company") Acquisition of Moda America LLC ("Moda") and extension of licence agreements with Emanuel Ungaro S.A. Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for world class brands, today announces that it has signed aheads of terms agreement to acquire 100% of Moda America LLC, a US company whichlicenses the 'Emanuel' label, the diffusion label of Emanuel Ungaro for the USmarket, for an aggregate cash consideration of US$ 5.5 million. This acquisition will: • Enable the launch of the Emanuel Ungaro and Ungaro collections in the USA, Canada and South America • Facilitate the launch of the JCC collections in these new territories • Add Moda turnover with effect from 1 January 2006 (2005 forecast US$26.0 million) • Give Marchpole worldwide reach with Moda infrastructure • Extend Moda's existing Emanuel Ungaro licence and distribution rights to include womenswear • Launch the diffusion Emanuel collection in the UK and Eire from Spring Summer 2007 We are also pleased to announce that as well as this acquisition, terms havealso been agreed with Emanuel Ungaro S.A. to extend the existing agreements forthe Emanuel Ungaro and Ungaro collections covering the European and Far Eastmarkets to include the important US market from Autumn Winter 2006. In addition to the licence extension, agreement has been reached with EmanuelUngaro S.A. for the distribution rights for the US market for all womenswearcollections of Emanuel Ungaro, including the designer ready to wear collection,and the diffusion collections under the Ungaro Fuchsia and Ungaro Fever labels,subject to agreement with the relevant licensees. Agreement has also beenreached for the Company to distribute the Emanuel Ungaro accessories collectionsubject to terms being finalised with the licensee. The Company has also been given the rights to extend Moda's US market 'Emanuel'diffusion collection into the UK and Ireland territories from the Spring Summer2007 season, and thereafter into further territories with the approval ofEmanuel Ungaro S.A. This acquisition and broad range of agreements extends the Company's reach intothe important US markets, giving the Company an infrastructure with which todevelop their European and Far East business, particularly the collections underthe Jean-Charles de Castelbajac ("JCC") brands. Terms of the acquisition The acquisition represents a Class 1 transaction for the Company and istherefore subject to Shareholder approval. A circular will be dispatched toShareholders as soon as practicable containing a notice of Extraordinary GeneralMeeting. The aggregate consideration for Moda as amounts to US$5.5 million in cashpayable in part on completion which is expected to be effective on 1 January2006, and the balance on 30 June 2006. The consideration will be funded byusing the financial resources available to the Company. Moda America LLC Moda America has been the US market licensee for the 'Emanuel by Emanuel Ungaro'collection since 2002 and has successfully developed the market. The Company isheadquartered in New York where it employs 15 staff and has significant showroomspace in which to show the collections. For the year ended 31 December 2004,Moda America LLC reported net turnover of US$ 17.8 million (£10.0 million)(2003: US$12.2 million, £7.0 million). Emanuel Ungaro S.A. has agreed to grant to the Company an extension of Moda'sexisting licence terms such that the licence agreement will now run to December2012, in line with the Company's existing agreements, with the last collectionunder the extended licence being Autumn Winter 2012. Reasons for the acquisition The 'Emanuel' label is well established in the US market with a strong customerbase and forecast sales for 2005 of US$ 26.0 million. Moda expects to dispatchgoods with a sales value of approximately US$ 14 million between August and theDecember year end. Combining the facilities, people and set up of the Moda business withMarchpole's existing sourcing abilities, design capability and infrastructurewill create sales and margin growth. This expansion into the US market has longbeen a strategic goal for the Company. Licence extensions and distribution agreements The licence extensions agreed with Emanuel Ungaro S.A. and announced today bringsignificant synergies to the Company. The existing Emanuel Ungaro and Ungarocollections which are currently sold into the UK, Europe, Middle East and FarEast markets will now also be distributed into the markets of the USA, Canadaand South America through the existing showrooms of Moda America LLC with effectfrom Autumn Winter 2006. The well established relationships that Moda America LLC has developed withdistributors in the USA can be leveraged to enhance promotion of Marchpole'sother brands. In particular, the Jean-Charles de Castelbajac ("JCC") brandswhich have a strong legacy in the USA on which to build. JCC has previously soldinto prestigious retailers such as Neiman Marcus, Barneys and a number ofindependent boutiques, and this agreement will allow the Company to continue todevelop these opportunities. The Company will also utilise the New York showrooms to sell the Emanuel Ungarowomenswear collections and accessories collections into the US market. The menswear diffusion collection previously sold by Moda America into the USmarket alone under the Emanuel label will, from Spring Summer 2007 be sold bythe Company from their London showrooms into their existing customer base in theUK and Ireland. Following this launch in the UK and Ireland, the potentialexists to expand on this agreement, and to launch this collection into furtherterritories. Commenting on the announcement, Chief Executive, Greg Tufnell, said: "Strategically the acquisition of Moda America LLC is the right stepping stonefor Marchpole, and establishes for the Company a strong presence in thesignificant US market. The further licence extensions and distributionagreements with Emanuel Ungaro S.A. allow the Company to develop on a trulyworldwide basis by leveraging the relationships and infrastructure that thisdeal brings. For further information please contact: Marchpole: 020 7908 7700Greg Tufnell, Chief ExecutiveJustin Hampshire, Finance DirectorMichael Morris, Executive Director Buchanan Communications: 020 7466 5000Tim Thompson / Nicola Cronk Shore Capital: 020 7408 4090Alex Borrelli / Dru Danford Notes to editors Marchpole This deal brings the 'Emanuel' label into the Marchpole stable which alreadyincludes the further two Emanuel Ungaro labels : Emanuel Ungaro and Ungaro aswell as labels Yves Saint Laurent, Boateng, Jean-Charles de Castelbajac ('JCC')and Jean-Charles de Castelbajac / Rossignol. The distribution agreement withEmanuel Ungaro will see Marchpole selling the ready to wear and diffusionwomenswear collections in the US market, and the licence extension agreementswill open up the US market for the currently produced menswear collections underthe Emanuel Ungaro and the Ungaro labels. Finally, the Emanuel collectioncurrently only distributed into the US market will be sold by the Company intothe UK and Ireland markets from Spring Summer 2007. In June this year, Marchpole announced its results for the year ended 31 March2005, with turnover up 62% at £32.5 million and profit before tax up 79% at £4.7million. For further information, please go to www.marchpole.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.